Launch
FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
What's New: Drugs RSS Feed · By FDA ·
The Brief
- The FDA approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection.
- The subcutaneous formulation covers all adult indications that the intravenous formulation of atezolizumab (Tecentriq) carries.
- The approval took place on September 12, 2024, according to the FDA announcement.
Why it matters
Adult patients on atezolizumab treatment may now receive the drug by subcutaneous injection instead of intravenous infusion, which can change how and where treatment is given.
Who’s affected
- Adult patients eligible for intravenous atezolizumab (Tecentriq)
- #fda
- #atezolizumab
- #subcutaneous
- #oncology
- #drug-approval
- #genentech
On September 12, 2024, the Food and Drug Administration approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq, Genentech, Inc.).
Timeline
FDA approves subcutaneous atezolizumab and hyaluronidase-tqjs
What's New: Drugs RSS Feed
FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection